Welcome to our dedicated page for Ultragenyx Pharmaceutical SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ultragenyx Pharmaceutical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ultragenyx Pharmaceutical's regulatory disclosures and financial reporting.
State Street Corporation reported beneficial ownership of 6,158,766 shares of Ultragenyx Pharmaceutical Inc. common stock on a Schedule 13G. This represents 6.3% of the class.
State Street reports 0 shares with sole voting or dispositive power, and 5,871,222 shares with shared voting power and 6,158,766 shares with shared dispositive power through its investment management subsidiaries.
Ultragenyx Pharmaceutical Inc. reported Q2 2026 revenue of $214 million, up 28% from Q2 2025, driven by higher Crysvita product and royalty revenue and expanding sales of Dojolvi, Evkeeza, and Mepsevii. Product sales were $112 million and Crysvita royalty revenue was $102 million in the quarter.
Net loss for Q2 2026 narrowed to $92 million (basic and diluted net loss per share $0.90) from $115 million a year earlier as revenue growth outpaced operating expense increases. For the first six months of 2026, revenue was $350 million and net loss was $277 million. Cash, cash equivalents and marketable securities totaled $436 million as of June 30, 2026, with $294 million used in operating activities in the first half. Liabilities for sales of future Crysvita royalties were $1.20 billion, contributing to a stockholders’ deficit of $291 million. A February 2026 restructuring reduced headcount by about 10% and generated $30 million in charges, all settled by June 30, 2026. Key near-term catalysts include FDA Priority Review decisions for DTX401 (PDUFA August 23, 2026) and UX111 (PDUFA September 19, 2026), and pivotal GTX-102 data expected in late 2026; management states expectations for profitability in 2027.
Ultragenyx Pharmaceutical Inc. reported second quarter 2026 results, with total revenue of $214 million, up from $167 million a year earlier and the highest quarterly revenue in its history. Key contributors were Crysvita at $156 million, Dojolvi at $27 million, Evkeeza at $21 million and Mepsevii at $10 million.
The company recorded a net loss of $92 million, or $0.90 per share, compared with a net loss of $115 million, or $1.17 per share, in second quarter 2025. Cash, cash equivalents and marketable securities were $436 million as of June 30, 2026, with $97 million of net cash used in operations in the quarter.
Ultragenyx reaffirmed 2026 guidance for total revenue of $730 million to $760 million, Crysvita revenue of $500 million to $520 million, and Dojolvi revenue of $100 million to $110 million, and continues to target profitability in 2027. Upcoming catalysts include FDA PDUFA action dates for DTX401 on August 23, 2026 and UX111 on September 19, 2026, plus a pivotal Phase 3 GTX-102 data readout in Angelman syndrome.
Ultragenyx Pharmaceutical Inc. EVP and Chief Legal Officer Karah Herdman Parschauer reported a sale of 1,900 shares of common stock on August 3, 2026 at $24.92 per share under a Rule 10b5-1 trading plan. Following this transaction, she directly holds 92,562 shares, including previously reported RSU-based shares subject to vesting conditions.
Ultragenyx Pharmaceutical Inc. reports that Chief Financial Officer Howard Horn sold 4,696 shares of common stock on August 3, 2026 at $24.92 per share in an open-market or private transaction under a Rule 10b5-1 trading plan, and now directly holds 96,295 shares, including shares underlying RSUs that remain subject to vesting conditions.
Ultragenyx Pharmaceutical Inc. (RARE) has a planned sale of restricted securities reported by Howard Horn under a notice of proposed sale of securities. The filing lists up to 4,696 shares of common stock, to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $117,024.32 and CUSIP 98489224, on the NASDAQ market. These shares were acquired as Restricted Stock and Performance Shares dated March 1, 2025.
The filing also lists securities sold during the past three months by Howard Horn: 4,698 common shares sold on July 1, 2026 for $155,644.74, and 4,653 common shares sold on June 1, 2026 for $110,601.81.
Vanguard Portfolio Management LLC, together with certain affiliates, reports beneficial ownership of 6,853,427 shares of Ultragenyx Pharmaceutical Inc. common stock on an amended Schedule 13G as of June 30, 2026. This represents 6.95% of the outstanding class.
Vanguard has sole voting power over 63,292 shares and sole dispositive power over all 6,853,427 shares, with no shared voting or dispositive power. The reported holdings include securities held by Vanguard funds and managed accounts over which the reporting business units exercise voting and/or dispositive authority, but exclude positions held by other Vanguard affiliates whose ownership is disaggregated. Vanguard notes that its investment companies and other managed accounts have the right to receive dividends and sale proceeds from these securities, and that no other single person’s interest in the reported securities exceeds 5% of the class.
Vanguard Capital Management reports beneficial ownership of 5,058,419 shares of Ultragenyx Pharmaceutical Inc. common stock on a Schedule 13G. This represents 5.13% of the outstanding common stock.
Vanguard has sole power to vote 761,928 shares and sole power to dispose of 5,058,419 shares, with no shared voting or dispositive power. The filing aggregates holdings of Vanguard Capital Management LLC and certain affiliates and Vanguard funds over which they exercise dispositive and/or voting power. Vanguard entities and managed accounts have the right to receive dividends and sale proceeds from these securities, and no other single person’s interest exceeds 5% of the class.
BlackRock, Inc. has filed an amended Schedule 13G reporting its beneficial ownership of common stock of Ultragenyx Pharmaceutical Inc. BlackRock reports beneficial ownership of 8,141,384 shares, representing 8.3% of Ultragenyx’s outstanding common stock.
BlackRock has sole voting power over 7,991,763 shares and sole dispositive power over all 8,141,384 shares, with no shared voting or dispositive power. Various underlying clients and accounts have rights to dividends and sale proceeds, but no single person holds more than five percent of Ultragenyx’s outstanding common shares through these interests.
Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported an open-market sale of 4,698 shares of common stock at a price of $33.13 per share. After this transaction, he directly owns 100,991 shares. His reported holdings include shares underlying previously granted RSUs that vest over time.